473 related articles for article (PubMed ID: 15752679)
1. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR; Pressler T; Koch C; Høiby N
J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
[TBL] [Abstract][Full Text] [Related]
2. Long-term, low-dose azithromycin treatment reduces the incidence but increases macrolide resistance in Staphylococcus aureus in Danish CF patients.
Hansen CR; Pressler T; Hoiby N; Johansen HK
J Cyst Fibros; 2009 Jan; 8(1):58-62. PubMed ID: 18849202
[TBL] [Abstract][Full Text] [Related]
3. Improved lung function and body mass index associated with long-term use of Macrolide antibiotics.
Pirzada OM; McGaw J; Taylor CJ; Everard ML
J Cyst Fibros; 2003 Jun; 2(2):69-71. PubMed ID: 15463852
[TBL] [Abstract][Full Text] [Related]
4. Early aggressive eradication therapy for intermittent Pseudomonas aeruginosa airway colonization in cystic fibrosis patients: 15 years experience.
Hansen CR; Pressler T; Høiby N
J Cyst Fibros; 2008 Nov; 7(6):523-30. PubMed ID: 18693078
[TBL] [Abstract][Full Text] [Related]
5. Maintenance azithromycin treatment in pediatric patients with cystic fibrosis: long-term outcomes related to macrolide resistance and pulmonary function.
Tramper-Stranders GA; Wolfs TF; Fleer A; Kimpen JL; van der Ent CK
Pediatr Infect Dis J; 2007 Jan; 26(1):8-12. PubMed ID: 17195698
[TBL] [Abstract][Full Text] [Related]
6. Differences in prevalence and treatment of Pseudomonas aeruginosa in cystic fibrosis centres in Denmark, Norway and Sweden.
Knudsen PK; Olesen HV; Høiby N; Johannesson M; Karpati F; Laerum BN; Meyer P; Pressler T; Lindblad A;
J Cyst Fibros; 2009 Mar; 8(2):135-42. PubMed ID: 19157995
[TBL] [Abstract][Full Text] [Related]
7. Once-weekly azithromycin in cystic fibrosis with chronic Pseudomonas aeruginosa infection.
Steinkamp G; Schmitt-Grohe S; Döring G; Staab D; Pfründer D; Beck G; Schubert R; Zielen S
Respir Med; 2008 Nov; 102(11):1643-53. PubMed ID: 18701270
[TBL] [Abstract][Full Text] [Related]
8. Achromobacter xylosoxidans in cystic fibrosis: prevalence and clinical relevance.
De Baets F; Schelstraete P; Van Daele S; Haerynck F; Vaneechoutte M
J Cyst Fibros; 2007 Jan; 6(1):75-8. PubMed ID: 16793350
[TBL] [Abstract][Full Text] [Related]
9. [Macrolides, Pseudomonas aeruginosa and cystic fibrosis].
Guillot M; Amiour M; El Hachem C; Harchaoui S; Ribault V; Paris C
Arch Pediatr; 2006 Oct; 13 Suppl 1():S48-50. PubMed ID: 17370396
[TBL] [Abstract][Full Text] [Related]
10. Poor clinical outcomes associated with a multi-drug resistant clonal strain of Pseudomonas aeruginosa in the Tasmanian cystic fibrosis population.
Bradbury R; Champion A; Reid DW
Respirology; 2008 Nov; 13(6):886-92. PubMed ID: 18811887
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis.
Etherington C; Hall M; Conway S; Peckham D; Denton M
J Antimicrob Chemother; 2008 Feb; 61(2):425-7. PubMed ID: 18156280
[TBL] [Abstract][Full Text] [Related]
12. Early rise of anti-pseudomonas antibodies and a mucoid phenotype of pseudomonas aeruginosa are risk factors for development of chronic lung infection--a case control study.
Pressler T; Frederiksen B; Skov M; Garred P; Koch C; Høiby N
J Cyst Fibros; 2006 Jan; 5(1):9-15. PubMed ID: 16412706
[TBL] [Abstract][Full Text] [Related]
13. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
14. Clinical response to azithromycin in cystic fibrosis correlates with in vitro effects on Pseudomonas aeruginosa phenotypes.
Nguyen D; Emond MJ; Mayer-Hamblett N; Saiman L; Marshall BC; Burns JL
Pediatr Pulmonol; 2007 Jun; 42(6):533-41. PubMed ID: 17469154
[TBL] [Abstract][Full Text] [Related]
15. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: a marker of therapeutic success?--A 30-year cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection.
Johansen HK; Nørregaard L; Gøtzsche PC; Pressler T; Koch C; Høiby N
Pediatr Pulmonol; 2004 May; 37(5):427-32. PubMed ID: 15095326
[TBL] [Abstract][Full Text] [Related]
16. Pulmonary infection in mild variant cystic fibrosis: implications for care.
Lording A; McGaw J; Dalton A; Beal G; Everard M; Taylor CJ
J Cyst Fibros; 2006 May; 5(2):101-4. PubMed ID: 16426904
[TBL] [Abstract][Full Text] [Related]
17. Long-term daily high and low doses of azithromycin in children with cystic fibrosis: a randomized controlled trial.
Kabra SK; Pawaiya R; Lodha R; Kapil A; Kabra M; Vani AS; Agarwal G; Shastri SS
J Cyst Fibros; 2010 Jan; 9(1):17-23. PubMed ID: 19818694
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of azithromycin in plasma, blood, polymorphonuclear neutrophils and sputum during long-term therapy in patients with cystic fibrosis.
Wilms EB; Touw DJ; Heijerman HG
Ther Drug Monit; 2006 Apr; 28(2):219-25. PubMed ID: 16628134
[TBL] [Abstract][Full Text] [Related]
19. Pseudomonas aeruginosa biofilms in the respiratory tract of cystic fibrosis patients.
Bjarnsholt T; Jensen PØ; Fiandaca MJ; Pedersen J; Hansen CR; Andersen CB; Pressler T; Givskov M; Høiby N
Pediatr Pulmonol; 2009 Jun; 44(6):547-58. PubMed ID: 19418571
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis.
Nixon GM; Armstrong DS; Carzino R; Carlin JB; Olinsky A; Robertson CF; Grimwood K
J Pediatr; 2001 May; 138(5):699-704. PubMed ID: 11343046
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
